Performance of a novel spectroscopy-based tool for adjuvant therapy decision-making in hormone receptor-positive breast cancer: a validation study
ConclusionDPS showed high accuracy and predictive performance, was able to stratify patients into low or high-risk, and considering its cost and rapidity, has the potential to offer clinical utility. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - January 20, 2024 Category: Cancer & Oncology Source Type: research

The association between HER2-low status and survival in patients with metastatic breast cancer treated with Cyclin-dependent kinases 4 and  6 inhibitors: a systematic review and meta-analysis
ConclusionThe available evidence demonstrates a significantly higher risk of progression or death with CDK 4/6 inhibitors in HER2-low tumors. Further research is needed to improve outcomes in patients with HR+-HER2-low tumors. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - January 19, 2024 Category: Cancer & Oncology Source Type: research

Clinical impact of delaying initiation of adjuvant chemotherapy in patients with early triple negative breast cancer
ConclusionTiming of adjuvant systemic therapy can influence OS in TNBC patients. Efforts should be made to avoid unnecessary delays in administering chemotherapy to ensure timely initiation of systemic therapy and optimize patient outcomes. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - January 19, 2024 Category: Cancer & Oncology Source Type: research

Identification of patient subgroups who benefit from a behavioral intervention to improve adjuvant endocrine therapy adherence: a randomized-controlled trial
ConclusionsA subgroup of patients who received STRIDE exhibited improvements in AET adherence. The interrelatedness of moderators suggests an underlying profile of patients with lower symptom burden who benefitted most from the intervention.Study registrationNCT03837496. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - January 17, 2024 Category: Cancer & Oncology Source Type: research

Endosomal recycling inhibitors downregulate estrogen receptor-alpha and synergise with endocrine therapies
DiscussionOur data suggest that combining ERIs with hormone receptor antagonists may enhance their efficacy and reduce the emergence of drug resistance. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - January 16, 2024 Category: Cancer & Oncology Source Type: research

Factors influencing the first and the fifth years adherence to adjuvant endocrine therapy in breast cancer patients in a low income country
ConclusionThe proportion of patients who are not adherent to AET was high in both cohorts, and the rate of non-adherent patients rises over time. It is essential to incorporate screening methods for lack of compliance to AET, as well as measures to try to reduce non-persistence to the treatment, such as educating the patients on the benefits of the treatment, managing comorbidities through lifestyle changes and, therefore, reducing polypharmacy and, above all, detecting and treating very early the adverse effects of AET that might interfere with its correct use. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - January 15, 2024 Category: Cancer & Oncology Source Type: research

Multi-center retrospective review of vitiligo-like lesions in breast cancer patients treated with cyclin-dependent kinase 4 and 6 inhibitors
ConclusionClinical characteristics are similar to previously reported findings in case reports and series. We add topical ruxolitinib as a potential treatment option for these patients and include data regarding progression-free survival that should continue to be collected. No definitive conclusions can be made regarding survival benefits from our cohort. Clinicians should refer these patients to dermatologists to aid with management. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - January 15, 2024 Category: Cancer & Oncology Source Type: research

Impact of body mass index on pathological response after neoadjuvant chemotherapy: results from the I-SPY 2 trial
ConclusionWe found no difference in pCR rates by BMI with actual body weight-based neoadjuvant chemotherapy in this biologically high-risk breast cancer population in the I-SPY2 trial. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - January 12, 2024 Category: Cancer & Oncology Source Type: research

Treatment patterns of patients with HR+/HER2- metastatic breast cancer receiving CDK4/6 inhibitor-based regimens: a cohort study in the French nationwide healthcare database
ConclusionThis real-world analysis confirms the effectiveness of CDK4/6 inhibitor-based regimens in French patients and highlights the frequent use of chemotherapy as second line therapy. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - January 11, 2024 Category: Cancer & Oncology Source Type: research

Polypharmacy, over-the-counter medications, and aromatase inhibitor adherence in early-stage breast cancer
ConclusionBaseline use of prescription medications but not OTCs was associated with increased AI persistence. Future research is needed to understand how this can be utilized to promote AI adherence. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - January 10, 2024 Category: Cancer & Oncology Source Type: research

The COVID-19 pandemic and its effects on follow-up of patients with early breast cancer: A patient survey
ConclusionsDespite limited evidence of effectiveness of routine in-person assessment, patients continue to place importance on regularly scheduled in-person follow-up. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - January 9, 2024 Category: Cancer & Oncology Source Type: research

Characterizing attitudes related to future child-bearing in young women diagnosed with early-stage breast cancer
ConclusionMany young women diagnosed with early-stage breast cancer prioritize childbearing. Interest in having a biologic child was not associated with standard prognostic risk factors. Interest decreased with increasing hypothetical recurrence risk, though some patients remained committed to future childbearing despite near certain hypothetical risk. Individual risk assessment should be included in family-planning discussions throughout the continuum of care as it can influence decision-making. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - January 9, 2024 Category: Cancer & Oncology Source Type: research

The anti-proliferative effects of a frankincense extract in a window of opportunity phase ia clinical trial for patients with breast cancer
ConclusionBoswellia serrata inhibited breast cancer proliferation and was well-tolerated in a Phase Ia window of opportunity trial. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - January 9, 2024 Category: Cancer & Oncology Source Type: research

Integrated analysis of diverse cancer types reveals a breast cancer-specific serum miRNA biomarker through relative expression orderings analysis
ConclusionOur study provides evidence that utilizing serum miRNA pairs can offer significant advantages for BrC-specific diagnosis in clinical practice by directly comparing serum samples with BrC to other cancer types. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - January 8, 2024 Category: Cancer & Oncology Source Type: research

Association between trajectories of prescription opioid use and risk of opioid use disorder and overdose among US nonmetastatic breast cancer survivors
ConclusionsAmong Medicare nonmetastatic breast cancer survivors receiving systemic endocrine therapy or adjuvant chemotherapy, compared with early discontinuation, low-dose or moderate-dose opioid use were associated with six- to sevenfold higher OUD/overdose risk. Breast cancer survivors at high-risk of OUD/overdose may benefit from targeted interventions (e.g., pain clinic referral). (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - January 8, 2024 Category: Cancer & Oncology Source Type: research